Nonlinear Dynamics Rolls out new Strategy for Proteomics
News Apr 04, 2007
Nonlinear Dynamics has announced that it is rolling out a brand new strategy that enables the use of multiple techniques in proteomics research. A range of new products is being launched at ABRF 2007, Tampa, Florida, to support this new strategy.
Recent publications have highlighted that the overlap between 2D and LC-MS for proteomics analysis can be as little as 10%, consequently researchers should use both techniques for more complete coverage. Furthermore, the use of correct statistical tests is vital to ensure valid scientific conclusions are drawn.
Nonlinear has expanded its Progenesis range to provide researchers with the analysis tools to achieve this goal.
Progenesis SameSpots for 2D image analysis was released last year and has received an overwhelming response from proteomics researchers. Version 2.0 is the definitive version with many new features to give even greater improvements in speed, objectivity and statistical power.
The launch of the Progenesis LC-MS expression analysis software, which utilises the advanced technology developed for the SameSpots approach, means users can apply the power of SameSpots to mass spec based proteomics and get the same benefits that this unique workflow delivers.
Progenesis Stats is an easy-to-use, multivariate statistical analysis tool that allows further interrogation of results generated from both Progenesis SameSpots and Progenesis LC-MS. It answers the key questions on complete data so researchers don’t miss biological changes which could be significant to their research.
Will Dracup, CEO of Nonlinear Dynamics said, “So far proteomics has struggled to provide results everyone believes that it should be capable of. We have been working on a strategy to help tackle this issue for years now and it’s great to be finally rolling it out both to our existing customers and to the many new customers who are switching to Nonlinear software. We are committed to driving proteomics into a new era and these new products underline that commitment.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.